Medicine
fromFast Company
2 weeks agoSanofi market value tanks following weak results on eczema drug trials
Amlitelimab met Phase III endpoints but showed weaker efficacy than Dupixent, triggering a >10% Sanofi share drop and concern over replacing Dupixent post‑patent expiry.